Madrigal Pharmaceuticals, Inc. clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 0 with minor changes only.

1. Notable

   Rezdiffra® With Concomitant Therapies Commonly Used…Rezdiffra® With Concomitant Therapies Commonly Used · Comorbidities in Adults With MASH and F2-F3 Fibrosis

   Recruitment opened

   Also in this update: Trial sites expanded: 0 → 16 locations; Start date changed from estimate of Sep 2026 to Oct 7, 2026

   Madrigal Pharmaceuticals, Inc.·Phase 4· NCT07848191· Registry history of NCT07848191 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

2. Notable

   Resmetirom · MASH and HFpEF

   Recruitment opened

   Also in this update: Trial sites expanded: 0 → 5 locations

   Madrigal Pharmaceuticals, Inc.·Phase 1· NCT07830758· Registry history of NCT07830758 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.